This aspect renders hnRNP K overexpressing-cells sensitive to BET-bromodomain-inhibition both in vitro and in transplantation models, opening out a new treatment strategy for DLBCL patients [83]. This evidence concerns the gene HNRNPK and diffuse large B-cell lymphoma.